TriangleCladribine (NCT00412594)
Cladribine trial for Hairy Cell Leukemia (NCT00412594). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with hairy cell leukemia confirmed by bone-marrow examination. Untreated patients and those whose disease returned after no more than one prior treatment may enter. Active infections exclude participation.
The idea: cladribine damages DNA, while rituximab directs an immune attack against CD20-bearing cells. Cladribine infusions run daily for five days. Weekly rituximab infusions start on day twenty-eight and continue for eight weeks. Marrow tests assess remaining leukemia; researchers monitor toxicity.
This phase 2 study plans 150 patients. Farhad Ravandi-Kashani leads at MD Anderson, Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.